Search API

RiVax Ricin Toxin Vaccine Description

Soligenix, Inc. RiVax® vaccine is a proprietary heat-stable recombinant subunit vaccine developed to protect people against exposure to ricin toxin. RiVax contains a genetically altered version of a Ricin Toxin A (RTA) chain containing two mutations that inactivate the ricin molecule's toxicity, invented initially at the University of Texas Southwestern. 

RiVax primarily consists of two components: 1.) A modified form of the A-chain of the ricin toxin. The modifications have removed the biological activity of the protein while still retaining its shape to trigger an effective antibody response; 2.) Aluminum ("alum") as an adjuvant. RiVax induces human adaptive immune systems to produce antibodies that recognize and bind ricin toxin, preventing it from getting inside cells and killing them. After intramuscular injection with RiVax, IgG and other antibodies are produced, circulate within the body, and can mop up ricin whether inhaled, eaten, or injected.

RiVax uses Soligenix's proprietary ThermoVax® technology that creates a thermostabilized vaccine candidate that can be stored at room temperature for extended periods, making it compatible with U.S. government stockpiling requirements. The thermostabilized version of RiVax is produced by lyophilizing (freeze-drying) the vaccine in individual vials to form a solid white cake. This removes water and other components from the material, which would otherwise destabilize the protein. Instead, by using a proprietary process, the protein-aluminum combination remains intact.

The solid, lyophilized material can then be returned to a liquid form immediately before use by adding sterile water and mixing before injection. Because sterile water is also widespread and very stable, this results in an extremely convenient product that can be stored for extended periods. Long-term storage and ease of use are key attributes for a product that may be stockpiled.

Approval for RiVax is being developed under the U.S. Food and Drug Administration (FDA) "Animal Rule," which is applied to products where testing in clinical efficacy trials would be unethical. RiVax received Orphan Drug and Fast Track designations from the FDA. In addition, RiVax has received an Orphan Drug designation from the European Medicines Agency. As a new chemical entity, an FDA-approved RiVax vaccine has the potential to qualify for a biodefense PRV, which allows the holder an accelerated review of a drug application. 

On December 20, 2022, the Company announced RiVax®-Vaccinated NHP survival was statistically significantly correlated with an epitope-specific serum assay (EPICC) prior to challenge. The journal npj Vaccines published a related study on December 16, 2022.

The development of RiVax® has been funded through a series of grants from both the National Institute of Allergy and Infectious Diseases (NIAID) and the U.S. FDA, and ongoing development is sponsored by NIAID contract #HHSN272201400039C. 

Soligenix, Inc. is a late-stage biopharmaceutical company (Nasdaq: SNGX) focused on developing and commercializing products to treat rare diseases where there is an unmet medical need.

RiVax Indication

RiVax Ricin Toxin Vaccine is indicated to prevent death following exposure to a lethal dose of ricin toxin that causes cell death once it penetrates the cell membrane. Ricin toxin can penetrate cells within four hours of exposure. Depending on the route of exposure (ingestion, inhalation, or injection), ricin toxin has different initial symptoms. Regardless of the initial route of exposure, ricin poisoning results in death with sufficient exposure.

The Company says the successful development of an effective vaccine against ricin toxin may act as a deterrent against the actual use of ricin as a biological weapon and could be used to vaccinate military personnel and civilian emergency responders at high risk of potential exposure in the event of a biological attack. There are no FDA-approved prophylactic or post-exposure therapies for ricin toxin exposure.

RiVax Dosage

RiVax is administered as an intramuscular injection on 2 or 3 occasions, resulting in the adaptive immune system mounting an antibody response. After intramuscular injection with RiVax, IgG and other antibodies are produced and circulate within the body and can mop up ricin whether it was inhaled, eaten, or injected.

RiVax News

December 20, 2022 - Soligenix, Inc. announced today the publication of preclinical immunogenicity challenge studies for RiVax® demonstrating statistically significant correlates of protection predicting survival after lethal aerosolized ricin challenge in non-human primates.

November 4, 2021 - Soligenix, Inc. announced the publication of pre-clinical immunogenicity studies for RiVax® demonstrating enduring protection for at least 12 months post-vaccination. The article "Durable Immunity to Ricin Toxin Elicited by a Thermostable, Lyophilized Subunit Vaccine" has been accepted for publication in the journal mSphere. The article results from collaborative work with the Wadsworth Center of the New York State Department of Health.

December 8, 2020 - RiVax Ricin Toxin Vaccine is pursuing approval under the U.S. FDA "Animal Rule," applied to products where testing in clinical efficacy trials would be unethical.

RiVax Clinical Trials

RiVax® studies have been supported by a contract (#HHSN272201400039C) award of approximately $21.2 million from the National Institute of Allergy and Infectious Diseases (NIAID). 

NCBI Phase 1: A pilot clinical trial of a recombinant ricin vaccine in normal humans.

NCBI Phase 1B:  Pilot Phase IB Clinical Trial of an Alhydrogel-Adsorbed Recombinant Ricin Vaccine. Clinical Trial NCT00812071: Phase 1B Study of RiVax, a Vaccine to Prevent the Toxic Effects of Ricin (FDA-OPD)

These studies suggest that RiVax/alum is safe and induces higher titers of total and neutralizing antibodies.

nOPV2 Polio Vaccine Clinical Trials, Efficacy, Dosage, Side Effects

The type 2 novel oral polio (nOPV2) vaccine was produced by Indonesia-based PT Biofarma and is derived from the live, infectious virus. It has been 'triple-locked' through genetic engineering to prevent it from becoming harmful or producing mutations. As a result, nOPV2 is reported to be more genetically stable than previous oral polio vaccines (OPV), with a lower risk of reversion to neurovirulence and reduced likelihood of mutations that can cause paralysis. The nOPV2 vaccine began development in 2011 and is an attenuated serotype two poliovirus derived from a modified Sabin 2 infectious cDNA clone. OPV2 Candidate 1 (S2/cre5/S15domV/rec1/hifi3) and nOPV2 Candidate 2 (S2/S15domV/CpG40) were generated by modifying the Sabin-2 RNA sequence to improve phenotypic stability and make the strains less prone to reversion to virulence.

On November 13, 2020, the nOPV2 vaccine was deployed under the World Health Organization (WHO) Emergency Use Listing procedure (EUL) to enable rapid field availability in countries affected by circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks. To minimize the risk of serotype two vaccine-associated paralytic poliomyelitis (VAPP) and cVDPV2, trivalent OPV was withdrawn from routine immunization schedules in 2016, following the certification of global WPV2 eradication. This was followed by a worldwide switch from tOPV to bivalent OPV (types 1 and 3). The nOPV2 vaccine was WHO-Prequalified in December 2023. Using nOPV2 for outbreak response must meet specific WHO requirements under the EUL.

On August 13, 2025, The Lancet Infectious Diseases published results from a first-in-human, observer-masked, multicentre, phase 1 randomized controlled trial on the safety and immunogenicity of novel live-attenuated type 1 and type 3 oral poliomyelitis vaccines in healthy adults in the USA. This analysis concluded that nOPV1 and nOPV3 were well tolerated and showed immunogenicity and shedding profiles similar to those of mOPV1 and mOPV3, respectively, supporting the progression to Phase 2 studies.

In 2024, the WHO's Strategic Advisory Group of Experts on immunization (SAGE) recommended the broader rollout of nOPV2 to help stop persistent outbreaks of circulating variant poliovirus type 2 (cVDPV2) in some of the toughest places. As of 2025, approximately 2 billion nOPV2 doses had been administered globally, with a significant proportion in Africa. Field data estimates an 82% reduction in the risk of cVDPV2 emergence with nOPV2 use compared to Sabin mOPV2.

The Global Polio Eradication Initiative (GPEI) published the nOPV2 Frequently Asked Questions, Fact Sheetsheet, and Global cVDPV outbreak country list. It also published the Global OPV Stockpile Strategy for 2022-2026 and the nOPV2 Safety Monitoring, Management, and Stockpile Strategy guidance manuals. In December 2024, the Global Health Technologies Coalition honored the nOPV2's development consortium with its 2024 Innovating for Impact Award. As of 2025, the nOPV2 vaccine is not FDA-approved in the United States.

nOPV2 Polio Vaccine Breakthrough Cases

The U.S. CDC reported that in 2024, cVDPV2 outbreaks were linked to the use of nOPV2 in 19 countries. These findings highlight that cVDPVs can develop with nOPV2 use when the timing and quality of vaccination responses are suboptimal, 

nOPV2 Polio Vaccine Availability 2025

Since the WHO granted emergency use listing in May 2021, approximately 35 countries have distributed nOPV2 doses. The WHO granted prequalification to PT Bio Farma and Biological E. Limited. In 2024 and 2025, Angola, Indonesia, Kenya, Liberia, the Republic of Sudan, Uganda, Papua New Guinea, and Gaza launched nOPV2 vaccination campaigns.

nOPV2 Polio Vaccine U.S. CDC

The U.S. CDC Advisory Committee on Immunization Practices (ACIP) presentations on February 28, 2024, included an Introduction and Considerations for the Potential Use of nOPV2 as an Outbreak Control Measure in the U.S. ACIP presentation on October 19, 2022, confirmed the nOPV2 is more genetically stable and less likely to be associated with the emergence of cVDPV2 and can provide mucosal immunity to limit the virus's spreading among IPV-vaccinated people. On September 22, 2023, the CDC reported a preliminary estimate suggesting that cVDPV2 emergencies occur after mOPV2 use at a rate of 1 per 10 million mOPV2 doses administered; for nOPV2, this rate is approximately 10 times lower at 1 per 100 million doses.

nOPV2 Polio Vaccine Development

The nOPV2 vaccine's development began in 2011 through a consortium of experts led by the Bill & Melinda Gates Foundation, the U.K. National Institute for Biological Standards and Controls (NIBSC), the U.S. Centers for Disease Control and Prevention (CDC), PATH.org, and the University of California at San Francisco as an essential new tool in the fight against cVDPV2. Since 2015, PATH has served as the convener of the nOPV2 product development consortium. On June 4, 2019, The Lancet published the findings of the initial Phase 1 clinical trial conducted in 2017 at the University of Antwerp, which demonstrated that nOPV2 is safe and efficacious. In April 2022, the WHO's Strategic Advisory Group of Experts on Immunization (SAGE) noted the safety and genetic stability data on nOPV2, confirming the vaccine's genetic stability and non-inferior immunogenicity compared with the monovalent oral polio vaccine type 2 (mOPV2). And nOPV2 is comparable with mOPV2 in terms of viral fecal shedding parameters. On March 28, 2023, the SAGE recommended that it be the preferred polio vaccine for response to cVDPV2 outbreaks wherever possible. In December 2023, the WHO issued nOPV2   prequalification approval under its EUL regulatory pathway. nOPV2 is the first vaccine to be WHO-prequalified after EUL. 

nOPV2 Polio Vaccine for Children

A Phase 3 clinical trial, funded by the Bill & Melinda Gates Foundation, concluded in February 2024 and demonstrated that the nOPV2 polio vaccine is immunogenic and safe in infants and young children in The Gambia. The data support the licensure and WHO prequalification of nOPV2.

nOPV2 Polio Vaccine Effectiveness

The Lancet Infectious Diseases published results from an observational cohort study on January 15, 2024, that included 5,635 eligible children, of which 97.7% received at least one dose of nOPV2. Poliovirus type 2 seroconversion rates were 70% (95% CI, 62-78; 87 of 124 children) following one dose of nOPV2 and 91% (95% CI, 85-95; 113 of 124 children) following two doses. Poliovirus excretion on day 7 was lower after the second round (162 of 459 samples; 35·3%, 95% CI 31·1 to 39·8) than after the first round (292 of 658 samples; 44·4%, 40·6 to 48·2) of the campaign (difference –9·1%; 95% CI –14·8 to –3·3), showing the induction of mucosal immunity. There was no axillary perature increase or baseline symptoms following either round of the campaigns. There were no adverse events of special interest or other safety signals of concern. 

In January 2024, Martin Faye and Maria Dolores Fernandez-Garcia published a comment in The Lancet Infectious Diseases, concluding that continued research is necessary to understand the real-world impact of the nOPV2 vaccine. This includes more field investigations and the long-term characterization of the genetic stability of nOPV2 through the sequencing of viral isolates. The Clinical Development and Evidence Summary was updated in April 2023.

nOPV2 Polio Vaccine Breakthrough Cases

According to the CDC's Morbidity and Mortality Weekly Report, from August 2021 to July 2023, seven cVDPV2 emergences of nOPV2 origin were detected in 61 paralytic cases and 39 environmental surveillance (sewage) samples from six African countries. The isolates exhibit limited divergence from the parental nOPV2 vaccine strain in the VP1 capsid protein-coding region (6-16 nucleotide substitutions), indicating that surveillance detected the emergence relatively early after vaccination. 

The GPEI received notification on March 16, 2023, of the detection of cVDPV2 in seven children with acute flaccid paralysis (AFP) in Burundi and the Democratic Republic of the Congo (DRC) linked with the nOPV2 vaccine. The WHO reported on May 12, 2023, that nOPV2 retains its enhanced genetic stability compared to Sabin OPV2. Only 2% of all isolates reported so far have shown evidence of losing essential genetic modifications that reduce neurovirulence through recombination, and these have been detected only in Africa, contrary to the expected 75% for Sabin OPV2.

nOPV2 Polio Vaccine Indication

The WHO SAGE recommends offering nOPV2 and IPV vaccines during polio outbreaks. A research study published in npj Vaccines on February 11, 2022, confirms that nOPV2 is more stable against virulent mutations than licensed OPV2. This study directly assesses whether shedding nOPV2 virus is comparable to shedding OPV2 virus in the same groups. Furthermore, it shows that the attenuated nOPV2 vaccine is more resistant to reversion than OPV2. Therefore, on December 9, 2021, the WHO recommended that all travelers to polio-affected areas be fully vaccinated against polio. Additionally, residents (and visitors staying for more than 4 weeks) from regions with polio outbreaks should receive an additional dose of oral polio vaccine or inactivated polio vaccine within 1 to 12 months of travel. On March 30, 2022, the GPEI released an updated version of the Standard Operating Procedures to guide the management of poliovirus outbreaks worldwide.  

nOPV2 Vaccine Side Effects

A review of safety data on the first 65 million doses of nOPV2 used for outbreak response by the independent Global Advisory Committee on Vaccine Safety concluded that there were no apparent safety concerns. In April 2024, the U.S. CDC published "Novel Oral Poliovirus Vaccine 2 Safety Evaluation during Nationwide Supplemental Immunization Activity, Uganda, 2022," which concluded that no safety signals were identified using a multipronged approach combining passive and active surveillance.

nOPV2 Vaccine Virus Shedding

The Journal of Infectious Diseases, Volume 226, Issue 5, September 1, 2022, published results from clinical studies that found poliovirus shedding data were available from 621 initially reverse-transcription PCR–negative infants. Seven days after dose 1, 64.3% of mOPV2 recipients and 31.3%–48.5% of nOPV2 recipients across groups shed infectious type 2 virus. Respective rates seven days after dose 2 decreased to 33.3% and 12.9%–22.7%, showing induction of intestinal immunity. Shedding of both nOPV2 candidates ceased at rates similar to or faster than mOPV2, and all vaccines showed evidence that the vaccine virus was replicating sufficiently to induce primary intestinal mucosal immunity.

nOPV2 Vaccine Dosing

A paper published by Mejia and colleagues in 2023 provides promising findings in favor of a shorter nOPV2 vaccination schedule, specifically for polio outbreak responses.

nOPV2 Comparison With mOPV2

While nOPV2 has led to the emergence of new cVDPV2, the number of cVDPV2 emergences is estimated to be approximately four times lower than it would have been if mOPV2 had been used.

nOPV2 Polio Vaccine News

August 28, 2025 - The WHO confirmed 9 million nOPV2 vaccines were available in PNG for administration.

August 11, 2025 - Dr Masahiro Zakoji, on behalf of the World Health Organization Representative in Papua New Guinea, emphasized the significance of the campaign: "This moment represents more than just a public health initiative—it is a bold step forward in our shared mission to secure the health and future of Papua New Guinea's youngest generation."

February 19, 2025 - The WHO confirmed that no additional polio cases have been reported in the Gaza Strip since a ten-month-old child was paralyzed in August 2024. Still, the new environmental samples from Deir al Balah and Khan Younis, collected in December 2024 and January 2025, confirm the transmission of poliovirus. 

December 20, 2024 - "The fight against polio has always been a story of partnerships…Many countries, partners, and individuals came together to develop this vaccine. This nOPV2 journey is an example of pushing the boundaries of innovation and doing it as a global team," commented Dr. Ananda Bandyopadhyay, Deputy Director of Technology, Research, and Analytics, Polio Team, Bill & Melinda Gates Foundation.

March 23, 2024: A scientific paper reviewed the development of nOPV2 through rollout and WHO prequalification. It is being applied to combat global health emergencies.

February 9, 2024 - PLOS One published: One billion doses and WHO prequalification of nOPV2: Implications for the global polio situation and beyond

January 9, 2024: John Konz, Ph. D., nOPV project director and global head of Polio at PATH, released a press release stating, "I would like to commend the Bio Farma team for their dedication to parallel efforts to meet demand under the EUL while completing critical activities needed to achieve full licensure and WHO prequalification."

September 22, 2023 - The U.S. CDC published Notes from Vaccine-Derived Poliovirus Type 2 Emergences Linked to Novel Oral Poliovirus Vaccine Type 2 Use — Six African Countries, 2021–2023

May 12, 2023—The WHO committee noted that in the African Region, which uses nOPV2, two new cVDPV2 patients were detected in the DRC, emerging from the novel use of OPV2.

May 10, 2023 - The Lancet published: Immunogenicity of novel oral poliovirus vaccine type 2 administered concomitantly with bivalent oral poliovirus vaccine: an open-label, non-inferiority, randomized, controlled trial. Conclusion: Co-administration of nOPV2 and bOPV interfered with immunogenicity for poliovirus type 2 but not for types 1 and 3. 

November 25, 2022 - The WHO released nOPV2 vaccines for use by Indonesia for approximately 95,000 children.

October 16, 2022 - The Gates Foundation announced a $1.2 billion commitment to support polio vaccination.

October 11, 2022 - Since the 68th session of the Regional Committee, vaccination campaigns have resumed in Afghanistan, and the Region has implemented outbreak response campaigns using the nOPV2 vaccine.

September 23, 2022: The Lancet published "A Novel Tool to Eradicate an Ancient Scourge: The Novel Oral Polio Vaccine Type 2 Story." Monitoring the use of nOPV2 has confirmed that it is more genetically stable and less likely to result in VDPV than the Sabin strain, suggesting that the global eradication of poliomyelitis may be slightly more attainable than previously thought.

June 17, 2022 - The U.S. CDC published Genetic Characterization of Novel Oral Polio Vaccine Type 2 Viruses During Initial Use Phase Under Emergency Use Listing — Worldwide, March–October 2021. nOPV2 is used to respond to poliovirus outbreaks with a comparatively low risk of generating new circulating strains. 

April 28, 2022 - The polio outbreak in Tajikistan marked the first detection of cVDPV2 in the WHO European Region. It was the first cVDPV2 outbreak in the world to be officially declared closed following supplemental immunization with the nOPV2 vaccine.

April 7, 2022 - The WHO's Strategic Advisory Group of Experts on Immunization is convening in Geneva to review updated data on the use of novel oral polio vaccine type 2 (nOPV2) and provide recommendations on initial planning for the cessation of OPV. The SAGE noted that a framework for a comprehensive analysis of nOPV2 performance is under development and requested periodic updates on the safety and genetic stability data of nOPV2.

February 11, 2022 - The journal NPJ Vaccines published a study that concluded: The available data from a key target age group for outbreak response confirm the superior genetic and phenotypic stability of shed nOPV2 strains compared to shed Sabin-2 and suggest that nOPV2 should be associated with less paralytic disease and potentially lower risk of seeding new outbreaks.

October 11, 2021 - Following a careful review of the safety and genetic stability data from mass immunization campaigns conducted with the novel oral polio vaccine type 2 (nOPV2), the Strategic Advisory Group of Experts on immunization (SAGE) today endorsed the transition to the following use phase for the vaccine.

March 13, 2021 - nOPV2 will be rolled out in Africa to fight vaccine-derived poliovirus type 2 outbreaks. Poor polio strains occur in under-immunized communities with limited access to safe water and sanitation.

July 29, 2021 - The journal Nature published the results of a study. Due to its safety, immunogenicity, and promising phenotypic stability, the use of nOPV2 under the Emergency Use Listing (EUL) is a prominent feature of the Global Polio Eradication Initiative's new strategy to halt the further spread of cVDPV21. The EUL has recently been granted for nOPV2-c1. The methods described here are now being applied to shed virus from paired phase 4 and phase 2 clinical trials of mOPV2 and nOPV2 in children and infants, allowing a more direct comparison of the molecular evolution and virulence of shed nOPV2 viruses with shed Sabin 2 in the age groups that will be the focus of outbreak responses.

nOPV2 Clinical Studies

nOPV2 polio vaccine has been studied in several clinical trials and is at various stages of development. Clinical summaries for the nOPV2 vaccine.

Ambirix Vaccine Description - 2022

Ambirix contains inactivated (killed) hepatitis A virus and ‘surface antigen’ (proteins from the surface) parts of the hepatitis B virus as active substances.

These vaccines are used to protect against the same diseases, but Twinrix Adult is given as a three-dose schedule, whereas Ambirix is given as 2 injections 6 to 12 months apart.

Protection against hepatitis B infections may not be obtained until after the second dose.

Ambirix is a registered trademark of the GlaxoSmithKline Group of Companies.

Ambirix Vaccine Indication

Ambirix is indicated in non-immune children and adolescents from 1 year up to and including 15 years of age for protection against hepatitis A and hepatitis B infection.

Ambirix should be used only when there is a relatively low risk of hepatitis B infection during the vaccination course.

Ambirix Vaccine Dosage

It is recommended that Ambirix be administered in settings where completion of the two-dose vaccination course can be assured. A dose of 1.0 ml is recommended for subjects from 1 year up to and including 15 years of age.

The standard primary course of vaccination consists of two doses, the first administered at the selected date and the second between 6 and 12 months after the first dose.

The recommended schedule should be adhered to. Once initiated, the vaccination's primary course should be completed with the same vaccine.

Vaccine Schedules for 2022

The CDC issues vaccine guidelines each year.  This year's recommended immunization schedules can be found here.

Ambirix Vaccine Clinical Studies

Three main studies of Ambirix were carried out in a total of 615 children from one year of age. All of the children received two doses of Ambirix six months apart. Two of the studies compared Ambirix with other vaccines against hepatitis A and B. The main measure of effectiveness was the proportion of vaccinated children who developed protective levels of antibodies one month after the last injection.

An additional study in 208 children compared the vaccine’s effectiveness when a six-month or a 12-month interval was used between the two injections.

CanSinoBio Ad5-EBOV Ebola Vaccine Description 2022

CanSinBio Ad5-EBOV is an adenovirus type 5 recombinant vector-based Ebola virus disease vaccine that protects against Ebola by relying on the recombinant replication-defective human adenovirus type-5 vector immune response. In addition, ad5-EBOV is manufactured as a lyophilized powder, highly stable, and does not require storage at ultra-low temperatures. This feature renders it viable for use in resource-limited tropical areas.

CanSino Biologics's Ad5-EBOV received NDA approval in China in October 2017. Ad5-EBOV has shown an acceptable stability profile and does not require ultra-low temperature storage conditions.

In 2014, a single-center, double-blind, placebo-control, dose-escalation phase 1 clinical trial was performed in Taizhou, China. The findings showed that the Ad5-EBOV vaccine was safe and robustly immunogenic. In this add-in study, the investigators intended to evaluate the safety and immunogenicity of a booster dose of the recombinant Ebola adenovirus vector vaccine (Ad5-EBOV) in healthy adults after primary immunization. The investigators expect that boosting immunization with the same vaccine for primary immunization is possible and could confer longer-lived protection when needed.

In July 2015, the First Affiliated Hospital of Zhejiang University launched a single-center, open, dose-escalation phase 1 clinical trial. This study will determine the safety and side-effect profile and immunogenicity of an investigational Ad5-EBOV vaccine in Healthy Adult Africans aged 18-60 years in China.

CanSino Biologics Inc.'s Ad5-EBOV vaccine is currently in China's national stockpile. In addition, CanSinoBio announced its new brand identity on April 24, 2022.

CanSinoBio Ad5-EBOV Ebola Vaccine Indication

Ad5-EBOV is indicated to prevent an infection of the Ebola disease. One shot of the high dose vaccine could mount a glycoprotein-specific humoral and T-cell response against the Ebola virus in 14 days. In addition, the company says, 'As compared to competing products from multinational companies, our Ad5-EBOV has shown a better stability profile and does not require ultra-low temperature storage conditions.'

CanSinoBio Ad5-EBOV Ebola Vaccine News 2014 - 2022

April 23, 2022 - Bloomberg.com reported a man infected with Ebola disease died in the north western province of the DRC.

August 12, 2020 - CanSino Biologics Inc. announced that it has successfully listed on the Sci-Tech Innovation Board (STAR Market) of the Shanghai Stock Exchange, making it the first "A+ H" dual listing vaccine company.

October 24, 2017 - Ad5-EBOV, the recombinant adenovirus vector-based vaccine, is the first Ebola shot based on the strain behind the recent epidemic in West Africa in 2014—the deadliest outbreak in recorded history.

October 14, 2014 - A Booster Dose of Ad5-EBOV in Healthy Adults After Primary Immunization.

CanSinoBio Ad5-EBOV Ebola Vaccine Clinical Trials

Yu Xuefeng, chairman and CEO of CanSinoBIO, points out that from a concept to an approved product, the development of the Ad5-EBOV vaccine took just a little more than three years, demonstrating CanSinoBIO’s strong capability for efficiently pushing a candidate through R&D and completing pre-clinical studies and clinical trials.